Evidence map›Paper›PMID 39060829›Full record

ReviewMolecular and cellular biochemistry2025

Gut microbiota regulates gut homeostasis, mucosal immunity and influences immune-related diseases.

Guoao Ding, Xuezhi Yang, Ying Li, Ying Wang, Yujie Du, Meng Wang, Ruxin Ye, Jingjing Wang, Yongkang Zhang, Yajun Chen and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Microorganisms · 2026
    Article
  17. Article
  18. Feline-DerivedMicroorganisms · 2026
    Article
  19. Effects of inactivatedAnimal nutrition (Zhongguo xu mu shou yi xue hui) · 2026
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Guoao Ding *School of Biological and Food Engineering, Hefei Normal University, Hefei, 230061, China.
Xuezhi Yang *Institute of Clinical Pharmacology, Key Laboratory of Anti-Inflammatory and Immune Medicine, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Medical University, Hefei, 230032, China.
Ying Li *School of Biological and Food Engineering, Hefei Normal University, Hefei, 230061, China.
Ying WangSchool of Biological and Food Engineering, Hefei Normal University, Hefei, 230061, China.
Yujie DuSchool of Biological and Food Engineering, Hefei Normal University, Hefei, 230061, China.
Meng WangSchool of Biological and Food Engineering, Hefei Normal University, Hefei, 230061, China.
Ruxin YeSchool of Biological and Food Engineering, Hefei Normal University, Hefei, 230061, China.
Jingjing WangSchool of Biological and Food Engineering, Hefei Normal University, Hefei, 230061, China.
Yongkang ZhangSchool of Biological and Food Engineering, Hefei Normal University, Hefei, 230061, China.
Yajun ChenSchool of Biological and Food Engineering, Hefei Normal University, Hefei, 230061, China.
Yan ZhangSchool of Biological and Food Engineering, Hefei Normal University, Hefei, 230061, China. zhangyanhfnu@gmail.com.

Funding

Hefei Normal University School-level research project 2022KJZD08Horizontal Development Project of Hefei Normal University HXXM2022129& HXXM2023075Key Laboratory of Anti-inflammatory and Immunological Drugs of the Ministry of Education of the People's Republic of China KFJJ-2023-08Natural Science Foundation of Higher Education in Anhui Province KJ2021ZD0113& 2022AH052166
6 · The paper itself

Abstract

The intestinal microbiome constitutes a sophisticated and massive ecosystem pivotal for maintaining gastrointestinal equilibrium and mucosal immunity via diverse pathways. The gut microbiota is continuously reshaped by multiple environmental factors, thereby influencing overall wellbeing or predisposing individuals to disease state. Many observations reveal an altered microbiome composition in individuals with autoimmune conditions, coupled with shifts in metabolic profiles, which has spurred ongoing development of therapeutic interventions targeting the microbiome. This review delineates the microbial consortia of the intestine, their role in sustaining gastrointestinal stability, the association between the microbiome and immune-mediated pathologies, and therapeutic modalities focused on microbiome modulation. We emphasize the entire role of the intestinal microbiome in human health and recommend microbiome modulation as a viable strategy for disease prophylaxis and management. However, the application of gut microbiota modification for the treatment of immune-related diseases, such as fecal microbiota transplantation and probiotics, remain quite challenging. Therefore, more research is needed into the role and mechanisms of these therapeutics.

Indexed as

Gastrointestinal MicrobiomeHomeostasisImmune System DiseasesImmunity, MucosalIntestinal MucosaAnimalsFecal Microbiota TransplantationHumansProbioticsGut microbiota gut homeostasis immune diseases disease prevention and treatment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.